Aktis Oncology (AKTS) insider entities convert preferred, buy shares

Rhea-AI Filing Summary

Aktis Oncology, Inc. director and 10% owner Kim Helen Susan reported indirect ownership changes tied to the company’s initial public offering. Investment entities Vida Ventures II, LLC and Vida Ventures II-A, LLC converted their Series A and Series B Redeemable Convertible Preferred Stock into Common Stock on a 3.8044-for-1 basis immediately before the IPO closing, with no additional cash paid. Following these conversions and additional purchases at $18 per share on the same date, Vida Ventures II, LLC held 5,671,825 shares of Common Stock and Vida Ventures II-A, LLC held 157,387 shares, over which various Vida Ventures entities and committee members, including the reporting person, may be deemed to share voting and investment power, subject to pecuniary-interest disclaimers.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Helen Susan

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		C(1)		4,859,370	A	(1)	4,859,370	I	See Footnote(2)
Common Stock	01/12/2026		P		812,455	A	$18	5,671,825	I	See Footnote(2)
Common Stock	01/12/2026		C(1)		134,842	A	(1)	134,842	I	See Footnote(3)
Common Stock	01/12/2026		P		22,545	A	$18	157,387	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Redeemable Convertible Preferred Stock	(4)	01/12/2026		C			14,838,250	(4)	(4)	Common Stock	3,900,284	$0	0	I	See Footnote(2)
Series A Redeemable Convertible Preferred Stock	(4)	01/12/2026		C			411,750	(4)	(4)	Common Stock	108,229	$0	0	I	See Footnote(3)
Series B Redeemable Convertible Preferred Stock	(5)	01/12/2026		C			3,648,750	(5)	(5)	Common Stock	959,086	$0	0	I	See Footnote(2)
Series B Redeemable Convertible Preferred Stock	(5)	01/12/2026		C			101,250	(5)	(5)	Common Stock	26,613	$0	0	I	See Footnote(3)

Explanation of Responses:

1. Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration.

2. These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

3. These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

4. The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

5. The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

	/s/ Karen McCarthy, as Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for AKTS on 01/12/2026?

The filing reports that entities associated with the reporting person converted Series A and Series B Redeemable Convertible Preferred Stock into Common Stock and also purchased Common Stock at $18 per share on 01/12/2026.

Who actually holds the Aktis Oncology (AKTS) shares reported in this Form 4?

The Common Stock is held by Vida Ventures II, LLC and Vida Ventures II-A, LLC. Vida Ventures management entities and committee members, including the reporting person, may be deemed to share voting and investment power, subject to each person’s pecuniary interest.

How many Aktis Oncology shares do the Vida Ventures entities hold after these transactions?

After the reported transactions, Vida Ventures II, LLC held 5,671,825 shares of Common Stock, and Vida Ventures II-A, LLC held 157,387 shares of Common Stock, as shown in the ownership columns.

What was the conversion ratio for Aktis Oncology’s preferred stock into Common Stock?

Both the Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering, without additional consideration.

Did the preferred shares in this Form 4 have an expiration date before converting?

The filing states that the Series A and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into Common Stock before the IPO closing.

Is the reporting person deemed to beneficially own all the AKTS shares reported?

The footnotes state that various Vida Ventures entities and committee members, including the reporting person, may be deemed to share voting, investment and dispositive power over the shares, and each person disclaims beneficial ownership except to the extent of their pecuniary interest.